GHAPPcast: Unable to Differentiate/Identify Between Slow & Fast Progressors - Need to Manage More Aggressively
Thank you to Intercept for your support of this podcast episode.Welcome to another episode of the GHAPP CLDF PBC Podcast Series, hosted by Andrea Gossard, NP. In this episode, we explore one of the mo...
28 Maalis 202518min
GHAPPcast: Better Understanding of PBC Patients Overall Liver Health and Managing Patients Holistically
Thank you to Intercept for your support of this podcast episode.Welcome to the eighth and final episode of the GHAPP CLDF PBC Podcast Series, hosted by Andrea Gossard, ARNP. In this powerful conclusio...
28 Maalis 202521min
GHAPPcast: Biomarkers Beyond ALP to Monitor for Measuring PBC UDCA Response to Therapy and Disease Progression
Thank you to Intercept for your support of this podcast episode.Welcome to the CLDF GHAPP PBC Podcast Series! In this episode of our eight-part series, host Andrea Gossard, NP, is joined by Christina ...
28 Maalis 202518min
Journal Club: Week 48 Efficacy of Guselkumab vs. Ustekinumab in Crohn’s Disease: Insights from GALAXI 2 & 3
Thank you to Johnson & Johnson for your support of this Journal Club Video Module.The GALAXI 2 and 3 Phase 3 trials provide critical insights into the 48-week efficacy of guselkumab and ustekinumab in...
26 Maalis 20255min
GHAPPcast: Simplifying Access: Evolving Drug Distribution Channels
In the final installment of our Simplified Access Series, we turn our focus to the evolving drug distribution landscape, including specialty pharmacy dynamics, hospital-based models, and the increasin...
25 Maalis 20259min
GHAPPcast: Simplifying Access: Prior Authorization Part 2
In Episode 2 of our Simplified Access Series, we continue our deep dive into practical strategies to streamline the prior authorization (PA) process and reduce delays in patient care. Nurse practition...
25 Maalis 202511min
GHAPPcast: Simplifying Access: Prior Authorization Part 1
Welcome to Episode 1 of our Simplified Access Series, where we explore real-world strategies to navigate prior authorizations and medication distribution challenges in hepatology and gastroenterology....
25 Maalis 202512min
Journal Club: Efficacy & Safety of Subcutaneous Guselkumab: 48-Week Results from the Phase 3 GRAVITI Study
Thank you to Johnson & Johnson for your support of this Journal Club Video Module.The GRAVITI study provides compelling Phase 3 data on guselkumab, an IL-23 p19 subunit inhibitor, demonstrating its ef...
18 Maalis 20254min
